Navigation Links
GW Research chosen as 'paper of the week' for blood coagulation discovery
Date:11/15/2012

WASHINGTON (Nov. 15, 2012) Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) will be featured as a top paper in next week's issue of the Journal of Biological Chemistry. Research by Rakesh Kumar, Ph.D., Catharine Birch McCormick Endowed Chair of the Department of Biochemistry and Molecular Biology and professor of biochemistry and molecular biology, and Beatriz Snchez-Solana, postdoctoral fellow at the department of biochemistry and molecular medicine, both at SMHS, has been selected as the journal's "Paper of the Week". The study, titled "p21-activated Kinase-1 Signaling Regulates Transcription of Tissue Factor and Tissue Factor Pathway Inhibitor," was chosen for its groundbreaking discovery of a new regulator of the blood coagulation cascade.

The research will be featured starting on Nov. 16, in Volume 287, No. 47 of the journal. The journal's editorial board members and associate editors determined the paper to be in the top two percent of manuscripts they will review in a year in significance and overall importance. About 50 to 100 papers are selected from the more than 6,600 published in the journal each year. The research will also be featured as the issue's cover image.

Blood coagulation, which many are aware of in terms of blood clotting after cuts and injuries, is a continuous process in the blood. It is a dynamic process, and there is a need to prevent and promote coagulation from time to time, for example, in the control of some diseases related to coagulation, such as cancer. As a whole, coagulation is regulated and initiated by a protein, named Tissue Factor (TF). TF works with many other proteins in a series of chain reactions in order to create coagulation. The activity of TF, a positive regulator of coagulation, is controlled by tissue factor pathway inhibitor (TFPI), a negative regulator, creating a balanced state.

"What was not known in the field is if there was any shared regulator or shared pathway, which cannot only regulate a positive regulator, but could also regulate a negative regulator of coagulation," said Kumar. "This is what we have found."

"We discovered for the first time that PAK1 [p21-activated Kinase-1] was implicated both in the regulation of the expression of TF, as well as TFPI," said Snchez-Solana.

P21-activated Kinase-1 (PAK1) has been widely implicated in cancer. There are many cancers where the expression of TF is up-regulated and outside research to support the idea that increasing expression of TF or a deregulated coagulation could contribute to cancer progression. The discovery made by Kumar and Snchez-Solana states that PAK1 is able to induce the expression of TF, but at the same time repress the expression of TFPI, promoting a hypercoagulant state. This is important not only to coagulation, but also coagulation as implicated in many cancers and diseases. By controlling the expression or activity of PAK1, which has been shown in this study to control coagulation, it can be used as a therapy for these coagulation processes.

"Should these findings be verified in animals, our research suggests it should be possible to change the rate of coagulation or the process of coagulation outcome by interfering or effecting the PAK1 signaling," said Kumar.


'/>"/>

Contact: Lisa Anderson
lisama2@gwu.edu
202-994-3121
George Washington University
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Research reveals first evidence of hunting by prehistoric Ohioans
3. Diabetes Research Institute develops oxygen-generating biomaterial
4. APS issues new policy requiring identification of sex or gender in reporting scientific research
5. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
6. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
7. U of Alberta researcher steps closer to understand autoimmune diseases
8. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
9. A project to research biological and chemical aspects of microalgae to fuel approach
10. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
11. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... July 20, 2017 , ... Dr. Asher Kimchi, Founder and ... of the 2017 IAC Awards at the 22nd World Congress on Heart Disease held ... four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ ... board of directors. This addition continues to strengthen and diversify VIC’s board. , ... and Chairman. “He is a highly accomplished business executive with a broad range of ...
(Date:7/20/2017)... DENVER and PLYMOUTH, Minn., July 20, 2017 ... LLC , a personalized genetic evaluations company, today ... under their partnership investigating a genetic mutation implicated ... to extend the partnership for a second case ... Last year, the KCNQ2 Cure Alliance and Pairnomix ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... solution to make clinical trial sites and study participants truly unified. TrialKit, a ... compliant (FDA 21 CFR Part 11) research studies entirely on mobile devices. With ...
Breaking Biology Technology: